Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anabolic agents for treating postmenopausal osteoporosis.

P J Meunier1

  • 1Department of Rheumatology and Bone Diseases, Pavillon F, Hôpital Edouard-Herriot, Lyon, France. meunier@lyon151.inserm.fr

Joint Bone Spine
|January 26, 2002
PubMed
Summary

Parathyroid hormone (PTH) is the only anabolic agent proven to reduce fracture risk in postmenopausal osteoporosis. Clinical trials show daily PTH injections significantly decrease vertebral and extravertebral fractures.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ethical guidelines for publication of research.

Calcified tissue international·2016
Same author

The use of different dual X-ray absorptiometry brands in a multicenter clinical trial: consequences and limits.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry·2013
Same author

In osteoporotic women treated with strontium ranelate, strontium is located in bone formed during treatment with a maintained degree of mineralization.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2009
Same author

Bone histomorphometry and bone quality.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2009
Same author

The effects of long-term raloxifene and estradiol treatments on bone in a patient with congenital aromatase deficiency.

Bone·2009
Same author

Influence of remodeling on the mineralization of bone tissue.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2009

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis treatment primarily focuses on fracture prevention.
  • Resorption inhibitors are common, but few anabolic agents demonstrate fracture risk reduction.
  • Parathyroid hormone (PTH) is a key anabolic agent for bone formation.

Purpose of the Study:

  • To evaluate the efficacy of parathyroid hormone (PTH) in reducing fracture risk in women with osteoporosis.
  • To assess the impact of PTH on bone mineral density (BMD) and potential side effects.

Main Methods:

  • A controlled clinical trial involving 1,637 women with osteoporosis.
  • Daily subcutaneous injections of PTH (1-34) at 20 or 40 microg doses for 21 months.
  • Fracture incidence, BMD changes, and hypercalcemia were monitored.

Related Experiment Videos

Main Results:

  • Daily PTH injections significantly reduced vertebral fractures by 65% and extravertebral fractures by 57% at the 20 microg/day dose.
  • Bone mineral density (BMD) increased by 9% at the lumbar spine and femoral neck.
  • Moderate postinjection hypercalcemia occurred in 11% of patients.

Conclusions:

  • Parathyroid hormone (PTH) is the only anabolic agent demonstrated to reduce vertebral and extravertebral fracture risk in postmenopausal osteoporosis.
  • PTH shows potential for use alone or in combination with resorption-inhibiting agents.
  • Further research into PTH's role in osteoporosis management is warranted.